DECIPHERING THE ECONOMIC BURDEN OF THYROID EYE DISEASE: A RETROSPECTIVE CLAIMS ANALYSIS
Author(s)
Stella Ko, PharmD1, David Tabano, MA, PhD2, Zhiyu Xia, PhD3, Rongrong Wang, MPH4, Ayesha Ahmed, PharmD4, Noha Keshk, BPharm, MS5, Sera-Leigh Ghouralal, PhD6, Giulio Barteselli, MD4.
1Student, University of Washington, Millbrae, CA, USA, 2Genentech, Denver, CO, USA, 3University of Washington, Kirkland, WA, USA, 4Genentech, South San Francisco, CA, USA, 5Purdue University, West Lafayette, IN, USA, 6Integrated Benefits Institute, San Francisco, CA, USA.
1Student, University of Washington, Millbrae, CA, USA, 2Genentech, Denver, CO, USA, 3University of Washington, Kirkland, WA, USA, 4Genentech, South San Francisco, CA, USA, 5Purdue University, West Lafayette, IN, USA, 6Integrated Benefits Institute, San Francisco, CA, USA.
OBJECTIVES: This study aimed to assess the burden of thyroid eye disease (TED), including healthcare resource use (HRU), total costs of care (TCOC), and productivity over 12 months.
METHODS: A retrospective cohort of patients with TED was identified using ICD-10 codes (Dx) among commercial and Medicare administrative claims from the MarketScan claims database. Patients aged ≥18 years were required to have an initial TED diagnosis between January 1, 2021 and March 31, 2024, with ≥12 months continuous enrollment pre-/post-index. A non-TED cohort was identified using 1:4 propensity score matching and randomized index date based on enrollment eligibility. Differences in HRU, TCOC, and productivity were assessed using a doubly robust approach. Quasipoisson generalized linear modeling (GLM) was used to calculate incident rate ratios (IRR) for HRU and productivity. Tweedie GLM was used to calculate cost ratios (CR) for TCOC.
RESULTS: This analysis included 16,694 TED and 65,881 non-TED patients. The TED cohort experienced higher rates of HRU, including hospitalization (IRR 2.49, P<0.001), emergency room visits (IRR 1.59, P<0.001) and outpatient services (IRR 1.49, P<0.001), compared with the non-TED cohort. CRs were also higher for the TED vs non-TED cohorts: TCOC (CR 2.40, P<0.001), inpatient services (CR 3.1, P<0.001), emergency room visits (CR 1.67, P<0.001), outpatient services (CR 2.94, P<0.001) and pharmacy claims (CR 1.31, P<0.001). Productivity outcomes were mixed in the TED vs non-TED cohorts, with no significant difference in absence (IRR 1.25, P=0.588) and absence hours (IRR 1.19, P=1.00), but higher rates of short-term disability claims (IRR 1.95, P<0.001) and short-term disability days (IRR 1.85, P<0.001).
CONCLUSIONS: TED drives higher HRU, TCOC, and short-term disability claims and days. Novel, value-driven therapies beyond current standard of care treatment options can support TED cost management for payers, employers and patients.
METHODS: A retrospective cohort of patients with TED was identified using ICD-10 codes (Dx) among commercial and Medicare administrative claims from the MarketScan claims database. Patients aged ≥18 years were required to have an initial TED diagnosis between January 1, 2021 and March 31, 2024, with ≥12 months continuous enrollment pre-/post-index. A non-TED cohort was identified using 1:4 propensity score matching and randomized index date based on enrollment eligibility. Differences in HRU, TCOC, and productivity were assessed using a doubly robust approach. Quasipoisson generalized linear modeling (GLM) was used to calculate incident rate ratios (IRR) for HRU and productivity. Tweedie GLM was used to calculate cost ratios (CR) for TCOC.
RESULTS: This analysis included 16,694 TED and 65,881 non-TED patients. The TED cohort experienced higher rates of HRU, including hospitalization (IRR 2.49, P<0.001), emergency room visits (IRR 1.59, P<0.001) and outpatient services (IRR 1.49, P<0.001), compared with the non-TED cohort. CRs were also higher for the TED vs non-TED cohorts: TCOC (CR 2.40, P<0.001), inpatient services (CR 3.1, P<0.001), emergency room visits (CR 1.67, P<0.001), outpatient services (CR 2.94, P<0.001) and pharmacy claims (CR 1.31, P<0.001). Productivity outcomes were mixed in the TED vs non-TED cohorts, with no significant difference in absence (IRR 1.25, P=0.588) and absence hours (IRR 1.19, P=1.00), but higher rates of short-term disability claims (IRR 1.95, P<0.001) and short-term disability days (IRR 1.85, P<0.001).
CONCLUSIONS: TED drives higher HRU, TCOC, and short-term disability claims and days. Novel, value-driven therapies beyond current standard of care treatment options can support TED cost management for payers, employers and patients.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE483
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), Sensory System Disorders (Ear, Eye, Dental, Skin)